CA088-1005
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component
Arms / Cohorts
Experimental, Arm D:Part 2: BMS-986393 + Elranatamab
Not Evaluated
Not yet accepting
Experimental, Arm C:Part 2: BMS-986393 + Iberdomide
Not Evaluated
Not yet accepting
Experimental, Arm B:Part 1: BMS-986393 + Mezigdomide
Not Evaluated
Accepting patients
Experimental, Arm B:Part 2: BMS-986393 + Mezigdomide
Not Evaluated
Not yet accepting
Experimental, Arm C:Part 1: BMS-986393 + Iberdomide
Not Evaluated
Accepting patients
Experimental:Arm E: BMS-986393 + Mezigdomide and Dexamethasone
Not Evaluated
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.